US 11,851,434 B2
Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
Steven W. Andrews, Boulder, CO (US); James F. Blake, Boulder, CO (US); Julia Haas, Boulder, CO (US); Yutong Jiang, Boulder, CO (US); Gabrielle R. Kolakowski, Boulder, CO (US); David A. Moreno, Boulder, CO (US); Li Ren, Boulder, CO (US); and Shane M. Walls, Boulder, CO (US)
Assigned to Array BioPharma Inc., Indianapolis, IN (US)
Filed by Array BioPharma Inc., Indianapolis, IN (US)
Filed on Oct. 29, 2021, as Appl. No. 17/514,684.
Application 17/514,684 is a continuation of application No. 16/478,071, granted, now 11,168,090, previously published as PCT/US2018/014279, filed on Jan. 18, 2018.
Claims priority of provisional application 62/447,862, filed on Jan. 18, 2017.
Prior Publication US 2022/0119396 A1, Apr. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4985 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) 16 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.
 
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of claim 1, or a pharmaceutically acceptable salt thereof.